Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 286 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Long-Term Follow-Up Confirms a Sustained Reduction in Deaths from Prostate Cancer... November 4, 2025 Former WNBA Player, Current Georgia Tech Coach Tasha Butts Diagnosed with... December 14, 2021 Study Suggests Watching Disney Movies May Improve Quality of Life for... May 26, 2020 ¿Las píldoras anticonceptivas afectan mi riesgo de cáncer? April 18, 2023 Load more HOT NEWS FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... Animal Shelters Are Honoring Healthcare Workers By Naming Shelter Dogs After... FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or...
